Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Miniaturized automated patch-clamp system combined with high-density microelectrode arrays for multi-scale functional mapping of neuronal networks

Obiettivo

More than one billion people worldwide (165 million in Europe) suffer from diseases of the central nervous system (CNS). With Europe's aging societies, the European Commission identified brain research as one of the key research areas under healthcare (https://ec.europa.eu/research/health/(si apre in una nuova finestra)). Many neurodegenerative diseases are still without cure (e.g. Parkinson’s, amyotrophic lateral sclerosis (ALS) and Alzheimer’s) and repeated failures in clinical trials increase the demand for novel screening technologies to be implemented in the early phases of drug discovery.

Recent studies show that synaptic dysfunction is involved in CNS diseases. New technologies for neuronal screening targeting synaptic and network activity, combined with disease model cells in vitro, will enable novel functional assays for CNS drug discovery. This project aims to develop MAPSYNE, a Miniaturized Automated Patch-clamp SYstem combined with high-density microelectrode arrays (HD-MEAs) for multi-scale functional mapping of NEuronal networks. Patch-clamp allows detection of synaptic events and action potentials (APs) of single cells, while HD-MEAs record APs of thousands of neurons in parallel (also track APs propagating along axons). Combining the two methods will allow access to neuronal electrical signals across spatial and temporal scales.

MAPSYNE's main objectives are (1) the development of hardware and software for a fully automated mini-patching system on HD-MEAs and (2) proof-of-concept experiments using primary and human induced pluripotent stem cell (h-iPSC)-derived neuronal networks.

MAPSYNE will be designed for long-term, label-free recording of cell cultures. Other applications include local application of drugs (e.g synaptic blockers on neuronal compartments). After this project, the ER envisions the commercialization of MAPSYNE, and eventually, its usage for preclinical CNS drug discovery.

Campo scientifico (EuroSciVoc)

Programma(i)

Argomento(i)

Meccanismo di finanziamento

MSCA-IF-EF-SE - Society and Enterprise panel

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) H2020-MSCA-IF-2017

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

MAXWELL BIOSYSTEMS AG
Contributo netto dell'UE
€ 187 419,60
Indirizzo
ALBISRIEDERSTRASSE 253
8047 ZURICH
Svizzera
PMI
Sì
Regione
Schweiz/Suisse/Svizzera Zürich Zürich
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Costo totale
€ 187 419,60